Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D97YGW
|
|||
| Drug Name |
SNDX-5613
|
|||
| Synonyms |
2169919-21-3; SNDX5613; SCHEMBL19693219; SCHEMBL19693428; EX-A4343; NSC825775; NSC-825775; HY-136175; CS-0120274
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | T lymphoblastic leukaemia [ICD-11: 2B33.4; ICD-10: C91-C95] | Phase 1/2 | [1] | |
| Company |
Syndax Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H47FN6O4S
|
|||
| Canonical SMILES |
CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
|
|||
| InChI |
1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
|
|||
| InChIKey |
FRVSRBKUQZKTOW-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Menin-MLL1 interaction (MEN1-KMT2A PPI) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04065399) A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.